Difference between revisions of "Vinflunine (Javlor)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=419548 NCI drug dictionary]: A bi-fluorinated derivative of the semi-synthet...") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Intravenous chemotherapy" to "Category:Intravenous medications") |
||
| Line 7: | Line 7: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| − | [[Category:Intravenous | + | [[Category:Intravenous medications]] |
[[Category:Vesicant chemotherapy]] | [[Category:Vesicant chemotherapy]] | ||
[[Category:Microtubule inhibitors]] | [[Category:Microtubule inhibitors]] | ||
[[Category:Vinca alkaloids]] | [[Category:Vinca alkaloids]] | ||
Revision as of 17:34, 25 July 2017
Mechanism of action
From the NCI drug dictionary: A bi-fluorinated derivative of the semi-synthetic vinca alkaloid vinorelbine with antitubulin, antineoplastic, and antiangiogenic activities. Vinflunine inhibits tubulin assembly without any stablization of assembled microtubules at concentrations comparable to those of other vinca alkaloids such as vincristine, vinblastine and vinorelbine; this effect on microtubule dynamics results in cell cycle arrest in mitosis and apoptosis. Compared to other vinca alkaloids, this agent binds weakly to the vinca-binding site, indicating that vinflunine may exhibit reduced neurotoxicity.
History of FDA approval
Not FDA approved; available in a number of other countries